Todos Medical Ltd. Stock price

Equities

TOMDF

IL0011392375

Biotechnology & Medical Research

Market Closed - OTC Markets 09:59:47 2024-03-26 am EDT 5-day change 1st Jan Change
0.000001 USD 0.00% Intraday chart for Todos Medical Ltd. 0.00% 0.00%
Sales 2020 5.21 Sales 2021 12.23 Capitalization 57.03M
Net income 2020 -29M Net income 2021 -43M EV / Sales 2020 7,726,750 x
Net Debt 2020 10.51M Net Debt 2021 31.56M EV / Sales 2021 7,243,615 x
P/E ratio 2020
-0.65 x
P/E ratio 2021
-0.92 x
Employees -
Yield 2020 *
-
Yield 2021
-
Free-Float 92.3%
More Fundamentals * Assessed data
Dynamic Chart
Todos Announces Notice of Allowance from Uspto for Patent Application Covering Use of Compositions in Tollovid?? and Tollovir?? Ingredients CI
Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics CI
Todos Medical Ltd. Enters into Exclusive Worldwide Automated Retail Supply Agreement with Smart Automated Retail Network CI
Todos Medical Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Todos Medical Terminates Tollovid Products License & Distribution Agreement with T-Cell Protect Hellas S.A CI
Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for Monkeypox PCR Test to US FDA CI
Todos Medical Announces USPTO Trademark Notice of Allowance for 3Cl Protease Biomarker Diagnostics Tollotest™ CI
Todos Medical Ltd. Enters into $50 Million Contract to Supply Tollovid(TM) and CBD Products to Retail Distributor Company Nerd Hemp CI
Todos Medical Initiates Validation Plan for PCR-Based Polio Testing at CLIA/Cap Laboratory Provista Diagnostics CI
Todos Medical, Ltd. Signs to Agreement with Its 3CL Protease Biology Theranostics Partner NLC Pharma, Ltd CI
Todos Medical Establishes Botanical Supplement Manufacturing Capabilities to Support Tollovid Global Expansion and Initiates CBD-A Production CI
Todos Medical Announces Saliva-Only Monkeypox Testing At Clia/Cap Clinical Lab Provista Diagnostics CI
Todos Medical, Ltd. Enrolls Female Long COVID Patient Unable to Secure Testing While Symptomatic for MonkeyPox into Provista Diagnostics Case Study Series CI
Todos Medical, Ltd Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women CI
Todos Medical Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
More news
1 month
0.00
Extreme 0
0.00
Current year
0.00
Extreme 0
0.00
1 year
0.00
Extreme 0
0.00
3 years
0.00
Extreme 0
0.64
5 years
0.00
Extreme 0
0.64
10 years
0.00
Extreme 0
1.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 41 20-01-04
Director of Finance/CFO 55 -
Chairman 53 17-06-21
Members of the board TitleAgeSince
Director/Board Member 48 20-04-16
Chief Executive Officer 41 20-01-04
Director/Board Member 80 16-02-26
More insiders
Date Price Change Volume
24-03-26 0.000001 0.00% 50,000
24-03-25 0.000001 0.00% 21,000
24-03-22 0.000001 0.00% 20,000
24-03-20 0.000001 0.00% 15,000
24-03-19 0.000001 0.00% 4,000

Delayed Quote OTC Markets, March 26, 2024 at 09:59 am EDT

More quotes
Todos Medical Ltd is a Israel-based clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer. The Companys Total Biochemical Infrared Analysis (TBIA) platform, represents a method for cancer screening of solid tumors using peripheral blood spectroscopy analysis. The process involves observing the immune system's response to tumor presence. TBIA analyzes the entire biochemical signatures spectrum including proteins, lipids, nucleic acids and carbohydrates of effected immune cells from peripheral blood, using infrared spectroscopy.
More about the company
  1. Stock
  2. Equities
  3. Stock Todos Medical Ltd. - OTC Markets